CA2199251A1 - Phosphonates et parathormone contre l'osteoporose - Google Patents

Phosphonates et parathormone contre l'osteoporose

Info

Publication number
CA2199251A1
CA2199251A1 CA002199251A CA2199251A CA2199251A1 CA 2199251 A1 CA2199251 A1 CA 2199251A1 CA 002199251 A CA002199251 A CA 002199251A CA 2199251 A CA2199251 A CA 2199251A CA 2199251 A1 CA2199251 A1 CA 2199251A1
Authority
CA
Canada
Prior art keywords
compound
bisphosphonic acid
acid
human
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002199251A
Other languages
English (en)
Inventor
Ann Dunbar Geddes
John Althorp Bevan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2199251A1 publication Critical patent/CA2199251A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Méthodes de traitement d'un sujet humain ou animal présentant un trouble du métabolisme osseux, comportant les étapes suivantes : a) administration audit sujet d'une quantité sûre et efficace d'un composé inhibiteur de la résorption osseuse durant une période allant d'environ 2 semaines à environ 6 mois; b) administration audit sujet d'une quantité sûre et efficace d'une parathormone, durant une période d'environ 3 à environ 12 mois. Les composés d'élection pour l'inhibition de la résorption sont les diphosphonates, les composés d'estrogènes et les composés d'antiestrogènes.
CA002199251A 1994-09-09 1995-09-06 Phosphonates et parathormone contre l'osteoporose Abandoned CA2199251A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30398194A 1994-09-09 1994-09-09
US303,981 1994-09-09

Publications (1)

Publication Number Publication Date
CA2199251A1 true CA2199251A1 (fr) 1996-03-14

Family

ID=23174525

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002199251A Abandoned CA2199251A1 (fr) 1994-09-09 1995-09-06 Phosphonates et parathormone contre l'osteoporose

Country Status (9)

Country Link
EP (1) EP0779813A4 (fr)
JP (1) JPH10505091A (fr)
KR (1) KR970705399A (fr)
CN (1) CN1157566A (fr)
AU (1) AU686019B2 (fr)
CA (1) CA2199251A1 (fr)
IL (1) IL115223A0 (fr)
PE (1) PE48597A1 (fr)
WO (1) WO1996007418A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
HU228400B1 (en) 2000-06-20 2013-03-28 Novartis Ag The use of bisphosphonates for treatment of osteoporosis
PT1328277E (pt) * 2000-10-27 2007-05-31 Schering Ag Compostos bisfosfónicos para o fortalecimento do osso cortical.
CN101355959B (zh) 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
CA2782640A1 (fr) 2009-12-07 2011-06-16 Michigan Technological University Hormone parathyroide de l'ours noir et ses procedes d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2124792C (fr) * 1991-12-17 2000-07-04 Ann D. Geddes Methodes de traitement de l'osteoporose par les biphosphonates et l'hormone parathyroidienne

Also Published As

Publication number Publication date
EP0779813A1 (fr) 1997-06-25
PE48597A1 (es) 1997-12-11
EP0779813A4 (fr) 1998-05-06
KR970705399A (ko) 1997-10-09
JPH10505091A (ja) 1998-05-19
AU3627795A (en) 1996-03-27
CN1157566A (zh) 1997-08-20
WO1996007418A1 (fr) 1996-03-14
AU686019B2 (en) 1998-01-29
IL115223A0 (en) 1995-12-31

Similar Documents

Publication Publication Date Title
AU663348B2 (en) Methods for the treatment of osteoporosis using bone-active phosphonates and parathyroid hormone
EP0573604B1 (fr) Procede de traitement de l'osteoporose
Hosking Advances in the management of Paget’s disease of bone
AU686458B2 (en) Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
AU686019B2 (en) Phosphonates and parathyroid hormone for osteoporosis
JPH0873376A (ja) 骨粗鬆症治療薬
EP0804202A1 (fr) Oestrogenes et hormone parathyroidienne utiles pour traiter l'osteoporose
JP2002538122A (ja) 天然に存在しないｆｐ選択的アゴニストおよび骨吸収抑制化合物を用いる骨体積の増加方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued